The FDA agreed to review Moderna’s experimental mRNA influenza vaccine after Moderna resubmitted its application with modifications.

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ...

Moderna Inc MRNA shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused ...

Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults ...

President Trump called Commissioner Marty Makary to the White House to discuss his frustration with the agency handling of ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

The FDA’s decision not to review the flu shot, which uses messenger RNA and is known as mRNA-1010, was unusual and drew ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the ...